Net losses at Westlake Village biotech firm MannKind fell to $9.32 million, or 4 cents per share for the first quarter, beating expectations of analysts as its chief product, Afrezza, saw revenue jump 58 percent. Sales of the inhalable insulin product rose to $8 million during the quarter ended March 31, while revenue from collaborations…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
